ASCO 2017 Congress Report
ASCO 2017 single articles:
• Preface
• EGFR-targeted treatments: insights from the adjuvant to the resistant setting
• New standards of care for ALK-positive disease
• Reducing the danger that arises from the CNS as a site of progression
• Diagnostics of EGFR-mutant disease: biomarkers with significant clinical implications
• Established targeted agents taking root in the HER2-positive setting
• Further defining the optimal use of immune checkpoint inhibitors
• Real-world utility of ctDNA NGS to identify matched targeted therapy
• Interview: Lung cancer in China: hurdles and progress
• Anti-angiogenic and immunotherapeutic approaches in mesothelioma
• Enhancing the profile of KRAS-mutant lung cancer
Full Report (English)